Neurocrine Biosciences | NBIX - Trade Creditors


Neurocrine Biosciences reported $691.3M in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
AbbVie USD 3.59B 28.65B Dec/2025
Acadia Pharmaceuticals USD 12.25M 1.34M Mar/2026
Agios Pharmaceuticals USD 13.75M 4.61M Mar/2026
ALKERMES USD 102.36M 5.59M Mar/2026
Alnylam Pharmaceuticals USD 126.63M 10.91M Mar/2026
Amgen USD 19.52B 1.37B Mar/2026
Biogen USD 358.5M 73.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Cytokinetics USD 24.71M 80.91M Mar/2026
Enanta Pharmaceuticals USD 1.88M 63K Dec/2025
Exelixis USD 24.15M 5.47M Mar/2026
Gilead Sciences USD 645M 70M Mar/2026
Halozyme Therapeutics USD 14.1M 6.8M Mar/2026
Incyte USD 228.62M 1.41B Mar/2026
Ionis Pharmaceuticals USD 26.03M 2.05M Mar/2026
Nektar Therapeutics USD 10.77M 4.79M Dec/2025
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Pfizer USD 4.51B 734M Mar/2026
Prothena USD 4.3M 1.58M Mar/2026
Regeneron Pharmaceuticals USD 1.03B 4.81B Mar/2026
Repligen USD 34.66M 4.65M Mar/2026
Rigel Pharmaceuticals USD 3.85M 3.44M Sep/2025
Sarepta Therapeutics USD 70.38M 210.46M Mar/2026
Teva Pharmaceutical Industries USD 2.6B 65M Mar/2026
Ultragenyx Pharmaceutical USD 42M 11M Mar/2026
Vertex Pharmaceuticals USD 3.47B 40.6M Mar/2026
Xoma USD 2.65M 1.52M Sep/2025